Key points are not available for this paper at this time.
Osimertinib is a recommended treatment for advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (
Share your take
Add a clinician perspective alongside expert commentary.
Lu et al. (2024) studied this question.